The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ANACOR PHARMA | COM | 032420101 | 68,259 | 4,067,892 | SH | SOLE | 4,067,892 | 0 | 0 | ||
GENVEC, INC. | COM | 37246C109 | 42 | 18,036 | SH | SOLE | 18,036 | 0 | 0 | ||
INTRALINKS | COM | 46118H104 | 91,846 | 7,584,296 | SH | SOLE | 7,584,296 | 0 | 0 | ||
REACHLOCAL | COM | 75525F104 | 35,041 | 2,756,966 | SH | SOLE | 2,756,966 | 0 | 0 |